Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.
about
Evaluation of protein biomarkers of prostate cancer aggressivenessPomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and ApoptosisRobotic radical prostatectomy: operative technique, outcomes, and learning curveThe role of SPINK1 in ETS rearrangement-negative prostate cancersalpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiationConcurrent chemoradiation for high-risk prostate cancerCancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancerNotch signaling in prostate cancer: a moving targetProstate cancer: ESMO Consensus Conference Guidelines 2012Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomyAssociation of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosisMaximal testosterone suppression in the management of recurrent and metastatic prostate cancerReconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer.Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signaturesCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersDeveloping a robotic prostatectomy service and a robotic fellowship programme - defining the learning curve.A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.Gene expression pathways of high grade localized prostate cancer.Outcomes after radical prostatectomy in men receiving previous pelvic radiation for non-prostate malignancies.Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniquesLong-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.Management of complications of prostate cancer treatment.Time trends in prostate cancer surgery: data from an Internet-based multicentre database.Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomyTargeting monoamine oxidase A in advanced prostate cancer.Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsyNovel diagnostic biomarkers for prostate cancer.Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy.Collagen I and III and metalloproteinase gene and protein expression in prostate cancer in relation to Gleason score.Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.Risk of urinary incontinence following prostatectomy: the role of physical activity and obesityPrehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial.Clinical management and burden of prostate cancer: a Markov Monte Carlo model.Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.
P2860
Q21261257-996F8053-7213-4D53-96A7-6C9181E00CE3Q21285102-B9FA66EA-02BC-4D34-939F-76880AE4D174Q24605129-C74B4D3E-6775-42E7-8499-48BB2D0F313AQ24647020-359A58B1-12CF-4705-9F04-D9F96DD44C42Q24669748-3173365F-754C-46D9-8C9E-F148361514AFQ26798912-AEEB0D23-6FAF-4063-B0D6-101CD3B6FBDAQ26852766-A912B51E-A642-4471-B3FB-3510CE4496A1Q27001047-2D30287B-2EA3-462F-97AC-C6E5B2CEB426Q27022847-84DC72B4-575D-47C0-8199-265BB589E158Q27025066-1818DE01-0349-4F98-94D4-1E6A0A5FC0D9Q28541425-3CB0F1AE-270D-4938-8EEB-4EC800C624E1Q29994552-2E258E4B-8731-4DD4-B7EB-328AB2A6E6C8Q30276626-82885200-469D-4756-BBC8-FFBBFC2D3290Q30300626-3033B394-5690-49C3-B8C5-B31FC1F882DEQ33248081-BA8B0802-262C-4CD1-A00D-CD7399121028Q33416583-A12EFDAD-BDD9-44ED-9F50-9FDA2C6659BFQ33624448-7A80D767-E6A6-4CED-A4D5-C780192934C2Q33625723-295256C9-974C-40FF-B80C-95CC04240F64Q33725993-6C607FDF-C361-4C51-8F0B-2E49D1D17195Q33759217-C63768C1-B6F7-4C30-8DF8-74908796ADCCQ33759725-007A488C-5A49-4188-991F-953E5F8FEA4BQ33827212-1685D5B1-913A-4636-ACF9-CEBB73ECAFFFQ33832517-EA9A0883-7F21-4517-B25A-5001D7744C57Q33834858-DCA77EED-2FF3-49DE-BAF8-AAAA0AB31562Q33922507-4235BBDE-8A66-491E-B7BA-5954FAFCE03DQ33965472-24CCE050-C399-4E54-9B47-60D8C0F0A83BQ33978360-0A2754FC-FC80-49D7-A678-88BD2A5022ECQ34007634-BEE473F6-119F-4ADF-AD6E-29BBD06D6B0BQ34013761-7569C14E-0E7B-4776-87FC-64FEF4EE5EDFQ34091402-F87DFD39-C7B9-4F8C-9EEF-732A8047B7D7Q34154664-C18556FD-673E-413E-AEC4-E69CA1EE86DDQ34186121-3F8373CA-ED4F-4893-81FF-2D0997B107B3Q34231678-9D389F19-E611-4619-94CB-29C7FE18A2A4Q34325482-E90CE0EC-69C5-4A1D-910D-DBF093F2002EQ34327452-6DA78071-F088-4743-8BC3-B33CFE71F080Q34554130-3CC39E85-FCE5-4881-A53A-436E3B0A6038Q34555966-45D16868-4607-46CD-9DD7-D17928AF2EE6Q34582174-0FE66957-5564-483B-A029-1F899F3E6DD9Q34634410-47943F08-F3F6-4418-A946-5CAEB2BA2213Q34756267-47B0CC53-06E4-4118-BFA1-75C280474610
P2860
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Long-term biochemical disease- ...... year Johns Hopkins experience.
@ast
Long-term biochemical disease- ...... year Johns Hopkins experience.
@en
Long-term biochemical disease- ...... year Johns Hopkins experience.
@nl
type
label
Long-term biochemical disease- ...... year Johns Hopkins experience.
@ast
Long-term biochemical disease- ...... year Johns Hopkins experience.
@en
Long-term biochemical disease- ...... year Johns Hopkins experience.
@nl
prefLabel
Long-term biochemical disease- ...... year Johns Hopkins experience.
@ast
Long-term biochemical disease- ...... year Johns Hopkins experience.
@en
Long-term biochemical disease- ...... year Johns Hopkins experience.
@nl
P2093
P1476
Long-term biochemical disease- ...... year Johns Hopkins experience.
@en
P2093
P304
P356
10.1016/S0094-0143(05)70163-4
P577
2001-08-01T00:00:00Z